Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Fred Ghali

Pediatric Dermatology Grapevine, TX Medical Doctor

NPI 1639286339 CMS profile 255273

1325 W Northwest Hwy, Grapevine, TX 76051

Open in the dashboard

General payments

$623,953

1,390 records reported · program years 2019–2025

Research payments

$6,940

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$283,823 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Fred Ghali of Grapevine, TX is reported in the CMS Open Payments database as having received $623,953 across 1,390 general payments and $6,940 in research payments paid to them. Separately, studies naming them as principal investigator received $283,823 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Pediatric Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $130,857 297
2024 General $94,280 227
2023 General $81,061 242
2023 Research $2,700 1
2022 General $67,942 214
2021 General $37,074 92
2021 Research $3,540 2
2020 General $95,872 147
2019 General $116,867 171
2019 Research $700 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fred Ghali
  • Pediatric Dermatology median
  • Middle half of Pediatric Dermatology
  • National median

In program year 2025, general payments to Fred Ghali were reported at $130,857. Among 172 Pediatric Dermatology profiles paid that year, the median was $302 and the middle half received between $110 and $2,128.

Show as a table
Year Fred Ghali Pediatric Dermatology median Middle half National median
2019 $116,867 $280 $89–$1,853 $163
2020 $95,872 $263 $71–$2,376 $114
2021 $37,074 $227 $69–$1,800 $132
2022 $67,942 $289 $69–$1,516 $149
2023 $81,061 $537 $114–$3,255 $160
2024 $94,280 $437 $114–$2,693 $164
2025 $130,857 $302 $110–$2,128 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $250,239 317 payments
  2. Regeneron Healthcare Solutions, Inc. $156,445 259 payments
  3. Sanofi-Aventis U.S. LLC $48,547 14 payments
  4. Galderma Laboratories, L.P. $42,718 103 payments
  5. Incyte Corporation $30,569 74 payments
  6. Dermavant Sciences, Inc. $25,979 23 payments
  7. Organon LLC $12,678 31 payments
  8. Regeneron Pharmaceuticals, Inc. $11,006 14 payments
  9. Novartis Pharmaceuticals Corporation $9,831 10 payments
  10. Arcutis Biotherapeutics, Inc. $9,779 42 payments
  11. Other $26,162 503 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $404,979 118 payments
  2. Consulting Fee $139,659 40 payments
  3. Travel and Lodging $37,670 151 payments
  4. Food and Beverage $28,010 1,072 payments
  5. Honoraria $13,400 4 payments
  6. Education $235 5 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $306,585 367 payments
  2. DUPIXENT Inflammation And Immunology $124,371 226 payments
  3. DUPIXENT Immunology $68,449 57 payments
  4. DUPIXENT Immunology And Inflammation $43,080 47 payments
  5. AKLIEF $32,450 45 payments
  6. OPZELURA $27,093 71 payments
  7. TAPINAROF $25,488 13 payments
  8. TWYNEO $17,872 19 payments
  9. VTAMA $13,100 37 payments
  10. ORACEA $10,582 7 payments
  11. Other $73,015 637 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Almirall LLC $3,540 2 payments
  2. Eli Lilly and Company $2,700 1 payment
  3. LEO Pharma AS $700 2 payments

Records

1,395 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Dermatology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record